919 East Hillsdale Boulevard
Suite 250
Foster City, CA 94404
United States
650 473 7700
https://www.geron.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 141
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. John A. Scarlett M.D. | Chairman of the Board, President & CEO | 1,25M | N/A | 1951 |
Ms. Michelle J. Robertson | Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer | 313,98k | N/A | 1967 |
Dr. Andrew J. Grethlein Ph.D. | Executive VP & COO | 761,52k | N/A | 1964 |
Mr. Scott Samuels | Executive VP, Chief Legal Officer & Corporate Secretary | 446,88k | N/A | N/A |
Ms. Aron Feingold | Vice President of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Ms. Shannon Odam | Senior VP & Chief People Officer | N/A | N/A | 1975 |
Ms. Melissa A. Kelly Behrs | Executive VP of Business Operations & Chief Alliance Officer | 693,57k | N/A | 1964 |
Mr. Anil Kapur | Executive VP of Corporate Strategy & Chief Commercial Officer | 603,03k | N/A | 1970 |
Mr. Edward E. Koval | Executive VP & Chief Business Officer | N/A | N/A | 1962 |
Dr. Faye Feller M.D. | Executive VP & Chief Medical Officer | N/A | N/A | 1983 |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporations ISS Governance QualityScore, Stand 1. Mai 2024, lautet 6. Die grundlegenden Scores sind Audit: 6, Vorstand: 5, Shareholderrechte: 9, Kompensation: 6.